Assembly Actions -
Lowercase Senate Actions - UPPERCASE |
|
---|---|
Jan 30, 2024 |
referred to consumer affairs and protection delivered to assembly passed senate |
Jan 17, 2024 |
advanced to third reading |
Jan 16, 2024 |
2nd report cal. |
Jan 09, 2024 |
1st report cal.112 |
Jan 03, 2024 |
referred to consumer protection |
Jan 31, 2023 |
referred to consumer protection |
Senate Bill S3518
2023-2024 Legislative Session
Sponsored By
(D) 34th Senate District
Current Bill Status - In Assembly Committee
- Introduced
-
- In Committee Assembly
- In Committee Senate
-
- On Floor Calendar Assembly
- On Floor Calendar Senate
-
- Passed Assembly
- Passed Senate
- Delivered to Governor
- Signed By Governor
Actions
Votes
co-Sponsors
(D) 15th Senate District
2023-S3518 (ACTIVE) - Details
2023-S3518 (ACTIVE) - Sponsor Memo
BILL NUMBER: S3518 SPONSOR: FERNANDEZ TITLE OF BILL: An act to amend the general business law, in relation to requiring prescription drug manufacturers to notify the attorney general of arrangements between pharmaceutical manufacturers resulting in the delay of the introduction of generic drugs PURPOSE OR GENERAL IDEA OF BILL: Enacts the "Manufacturer Disclosure and Transparency Act" to bring disclosure and transparency to the pay-for-delay deals that harm consum- ers by delaying generic drug competition with brand-name drugs. SUMMARY OF PROVISIONS: Section 1 establishes the title of the bill. Section 2 requires each pharmaceutical manufacturer doing business in this state that manufactures a brand-name prescription drug and enters
2023-S3518 (ACTIVE) - Bill Text download pdf
S T A T E O F N E W Y O R K ________________________________________________________________________ 3518 2023-2024 Regular Sessions I N S E N A T E January 31, 2023 ___________ Introduced by Sen. FERNANDEZ -- read twice and ordered printed, and when printed to be committed to the Committee on Consumer Protection AN ACT to amend the general business law, in relation to requiring prescription drug manufacturers to notify the attorney general of arrangements between pharmaceutical manufacturers resulting in the delay of the introduction of generic drugs THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM- BLY, DO ENACT AS FOLLOWS: Section 1. This act shall be known and may be cited as the "manufac- turer disclosure and transparency act". § 2. The general business law is amended by adding a new section 396- rrr to read as follows: § 396-RRR. DELAY OF INTRODUCTION OF GENERIC MEDICATIONS. 1. (A) EACH PHARMACEUTICAL MANUFACTURER DOING BUSINESS IN THIS STATE THAT MANUFAC- TURES A BRAND NAME PRESCRIPTION DRUG AND ENTERS INTO AN ARRANGEMENT, THROUGH AGREEMENT OR OTHERWISE, WITH ANOTHER PHARMACEUTICAL MANUFACTURER THAT HAS THE PURPOSE OR EFFECT OF DELAYING OR PREVENTING SUCH OTHER MANUFACTURER FROM INTRODUCING A GENERIC SUBSTITUTE FOR SUCH DRUG INTO THE MARKETPLACE SHALL, NOT LATER THAN THIRTY DAYS AFTER ENTERING INTO SUCH ARRANGEMENT, SEND NOTICE TO THE ATTORNEY GENERAL, IN A FORM AND MANNER PRESCRIBED BY THE ATTORNEY GENERAL, DISCLOSING THE NAME OF SUCH DRUG, THE WHOLESALE PRICE, THE DISEASE SUCH DRUG IS COMMONLY PRESCRIBED TO TREAT, THE MANUFACTURER OF SUCH DRUG, THE NAME OF THE GENERIC MANUFACTURER, AND THE LENGTH OF THE DELAY. (B) THE ATTORNEY GENERAL SHALL, NO LATER THAN THIRTY DAYS AFTER RECEIVING A NOTICE PURSUANT TO PARAGRAPH (A) OF THIS SUBDIVISION, SHARE THE INFORMATION WITH THE DRUG UTILIZATION REVIEW BOARD ESTABLISHED UNDER SECTION THREE HUNDRED SIXTY-NINE-BB OF THE SOCIAL SERVICES LAW, ALL MEDICAID MANAGED CARE PLANS, HEALTH CARRIERS AND PHARMACY BENEFITS MANAGERS DOING BUSINESS IN THE STATE IN A FORMAT AND MANNER PRESCRIBED BY THE ATTORNEY GENERAL. EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets [ ] is old law to be omitted. LBD00235-01-3
Comments
Open Legislation is a forum for New York State legislation. All comments are subject to review and community moderation is encouraged.
Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity, hate or toxic speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Attempts to intimidate and silence contributors or deliberately deceive the public, including excessive or extraneous posting/posts, or coordinated activity, are prohibited and may result in the temporary or permanent banning of the user. Comment moderation is generally performed Monday through Friday. By contributing or voting you agree to the Terms of Participation and verify you are over 13.
Create an account. An account allows you to sign petitions with a single click, officially support or oppose key legislation, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.